To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Hospitalizations in Long-… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Hospitalizations in Long-term Survivors of Childhood AML Treated with Allogeneic HSCT - an Adult Life after Childhood Cancer in Scandinavia (ALiCCS) Study

Conference contribution
Authors Mari Wilhelmson
Kirsi Jahnukainen
Jacek Winiarski
Jonas Abrahamsson
A Bautz
T Gudmundsdottir
L Madanat-Harjuoja
Anna Sällfors-Holmqvist
J Falck Winther
Henrik Hasle
Published in 38th NOPHO Annual meeting. Aalborg, Denmark 3-7 May
Publication year 2019
Published at Institute of Clinical Sciences, Department of Pediatrics
Language en
Subject categories Cancer and Oncology, Pediatrics


Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is effective in treating childhood acute myeloid leukemia (AML) but the long-term disease burden may be increased. In a population-based study, the standardized hospitalization rates ratios (SHRR) and absolute excess risks for disease specific hospitalizations were evaluated in 5-year survivors of AML treated at 0-17 years of age according to the NOPHO-AML protocols in four Nordic countries during 1984-2005. In total, 229 eligible AML survivors were identified in the NOPHO-AML database and the treatment data of 196 survivors could be linked to 5-year follow-up data in national hospital registries. After a median follow-up time of 12 (range 5–28) years, 35 out of the 97 survivors treated with allo-HSCT had been hospitalized (SHRR 2.8 (95% CI 2.0– 4.0) with increased risk for hospitalizations due to cardiovascular 8.7 (3.9–19), endocrine 12 (6.7–22), pulmonary 3.0 (1.8–5.2), gastrointestinal 4.0 (2.4–6.7), infectious 3.1 (1.3–7.6), neurological 4.4 (2.1–9.2) and uro-genital system conditions 2.9 (1.3–6.4). In comparison, after a median follow-up time of 11 (range 5–28) years, 21 out of the 99 survivors treated with chemotherapy alone had been hospitalized; SHRR 1.4 (0.9–2.1). Our results indicate that hospitalization rates are significantly increased in long-term survivors of childhood AML if treated with allo-HSCT but not in survivors treated with chemotherapy only.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?